160 related articles for article (PubMed ID: 32818095)
1. Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits.
Kim HM; Park YJ; Lee S; Son JY; Hong HK; Ham MH; Jin X; Chung JY; Park KH; Park KD; Woo SJ
Transl Vis Sci Technol; 2020 Mar; 9(4):7. PubMed ID: 32818095
[TBL] [Abstract][Full Text] [Related]
2. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.
Ahn SJ; Ahn J; Park S; Kim H; Hwang DJ; Park JH; Park JY; Chung JY; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):567-73. PubMed ID: 24398088
[TBL] [Abstract][Full Text] [Related]
3. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.
Park SJ; Oh J; Kim YK; Park JH; Park JY; Hong HK; Park KH; Lee JE; Kim HM; Chung JY; Woo SJ
Eye (Lond); 2015 Apr; 29(4):561-8. PubMed ID: 25592118
[TBL] [Abstract][Full Text] [Related]
4. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
[TBL] [Abstract][Full Text] [Related]
5. Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model.
Park SJ; Choi Y; Na YM; Hong HK; Park JY; Park KH; Chung JY; Woo SJ
Invest Ophthalmol Vis Sci; 2016 May; 57(6):2612-7. PubMed ID: 27258433
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
[TBL] [Abstract][Full Text] [Related]
8. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits.
Giannos SA; Kraft ER; Luisi JD; Schmitz-Brown ME; Reffatto V; Merkley KH; Gupta PK
Pharm Res; 2024 Jun; 41(6):1247-1256. PubMed ID: 38839719
[TBL] [Abstract][Full Text] [Related]
9. [Retina penetration of subconjunctival ranibizumab injection in the rabbit eye].
Zhao Y; Lei W
Zhonghua Yan Ke Za Zhi; 2015 May; 51(5):356-9. PubMed ID: 26311696
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
[TBL] [Abstract][Full Text] [Related]
11. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans.
Krohne TU; Liu Z; Holz FG; Meyer CH
Am J Ophthalmol; 2012 Oct; 154(4):682-686.e2. PubMed ID: 22818800
[TBL] [Abstract][Full Text] [Related]
12. Quantitative pharmacokinetic analyses of anterior and posterior elimination routes of intravitreal anti-VEGF macromolecules using published human and rabbit data.
Lamminsalo M; Urtti A; Ranta VP
Exp Eye Res; 2022 Sep; 222():109162. PubMed ID: 35760120
[TBL] [Abstract][Full Text] [Related]
13. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
[TBL] [Abstract][Full Text] [Related]
14. Binding to Ocular Albumin as a Half-Life Extension Principle for Intravitreally Injected Drugs: Evidence from Mechanistic Rat and Rabbit Studies.
Fuchs H; Igney F
J Ocul Pharmacol Ther; 2017 Mar; 33(2):115-122. PubMed ID: 28055308
[TBL] [Abstract][Full Text] [Related]
15. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
[TBL] [Abstract][Full Text] [Related]
16. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
Myers AC; Lövestam Adrian M; Bruun A; Ghosh F; Andréasson S; Ponjavic V
Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009
[TBL] [Abstract][Full Text] [Related]
17. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
Wang JW; Zhou MW; Zhang X; Huang WB; Gao XB; Wang W; Chen S; Zhang XY; Ding XY; Jonas JB
Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
[TBL] [Abstract][Full Text] [Related]
19. Role of the Fc Region in the Vitreous Half-Life of Anti-VEGF Drugs.
Joo K; Park SJ; Choi Y; Lee JE; Na YM; Hong HK; Park KH; Kim HM; Chung JY; Woo SJ
Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4261-4267. PubMed ID: 28850637
[TBL] [Abstract][Full Text] [Related]
20. Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye.
Chen JJ; Ebmeier SE; Sutherland WM; Ghazi NG
Eye (Lond); 2011 Nov; 25(11):1504-11. PubMed ID: 21921952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
